GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Minerva Neurosciences Inc (NAS:NERV) » Definitions » Shiller PE Ratio

Minerva Neurosciences (Minerva Neurosciences) Shiller PE Ratio : (As of Apr. 30, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Minerva Neurosciences Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Minerva Neurosciences Shiller PE Ratio Historical Data

The historical data trend for Minerva Neurosciences's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Minerva Neurosciences Shiller PE Ratio Chart

Minerva Neurosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Minerva Neurosciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Minerva Neurosciences's Shiller PE Ratio

For the Biotechnology subindustry, Minerva Neurosciences's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Minerva Neurosciences's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Minerva Neurosciences's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Minerva Neurosciences's Shiller PE Ratio falls into.



Minerva Neurosciences Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Minerva Neurosciences's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Minerva Neurosciences's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-1.2/129.4194*129.4194
=-1.200

Current CPI (Dec. 2023) = 129.4194.

Minerva Neurosciences Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -1.286 99.695 -1.669
201406 -8.476 100.560 -10.909
201409 -12.240 100.428 -15.773
201412 0.880 99.070 1.150
201503 -2.480 99.621 -3.222
201506 -2.160 100.684 -2.776
201509 -1.920 100.392 -2.475
201512 -2.800 99.792 -3.631
201603 -2.320 100.470 -2.988
201606 -1.440 101.688 -1.833
201609 -1.920 101.861 -2.439
201612 -2.240 101.863 -2.846
201703 -2.400 102.862 -3.020
201706 -2.160 103.349 -2.705
201709 -2.240 104.136 -2.784
201712 0.080 104.011 0.100
201803 -2.560 105.290 -3.147
201806 -2.560 106.317 -3.116
201809 -2.480 106.507 -3.014
201812 -2.720 105.998 -3.321
201903 -3.280 107.251 -3.958
201906 -2.560 108.070 -3.066
201909 -2.880 108.329 -3.441
201912 -6.160 108.420 -7.353
202003 -2.480 108.902 -2.947
202006 5.840 108.767 6.949
202009 -1.520 109.815 -1.791
202012 -1.440 109.897 -1.696
202103 -1.680 111.754 -1.946
202106 -1.980 114.631 -2.235
202109 -1.720 115.734 -1.923
202112 -3.990 117.630 -4.390
202203 -1.830 121.301 -1.952
202206 -1.630 125.017 -1.687
202209 -1.290 125.227 -1.333
202212 -1.260 125.222 -1.302
202303 -1.310 127.348 -1.331
202306 -1.120 128.729 -1.126
202309 -1.030 129.860 -1.027
202312 -1.200 129.419 -1.200

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Minerva Neurosciences  (NAS:NERV) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Minerva Neurosciences Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Minerva Neurosciences's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Minerva Neurosciences (Minerva Neurosciences) Business Description

Traded in Other Exchanges
Address
1500 District Avenue, Burlington, MA, USA, 01803
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It primarily focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, major depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and major depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
Executives
Ag Boehringer 10 percent owner BINGER STRABE 173, INGELHEIM AM RHEIN 2M 55216
Boehringer Ingelheim International Gmbh 10 percent owner 200 PARK AVENUE, C/O KLAUS H JANDER ESQ ROGERS & WELLS LL, NEW YORK NY 10166
Remy Luthringer officer: EVP and Head of R&D C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 286, WALTHAM MA 02451
Geoff Race officer: EVP and CFO C/O MINERVA NEUROSCIENCES, 1601 TRAPELO ROAD, SUITE 286, WALTHAM MA 02451
Frederick W Ahlholm officer: Chief Accounting Officer C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 286, WALTHAM MA 02451
Plc Barclays 10 percent owner 1 CHURCHILL PLACE, CANARY WHARF, LONDON X0 E14 5HP
David Kupfer director C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 284, WALTHAM MA 02451
Joseph H. Reilly officer: Chief Business Officer C/O MINERVA NEUROSCIENCES, 1601 TRAPELO ROAD, SUITE 286, WALTHAM MA 02451
Van Heek G Jan director ONE KENDALL SQUARE, CAMBRIDGE MA 02139
Richard E. Russell officer: President C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 284, WALTHAM MA 02451
William F Doyle director
Hans Peter Hasler director C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 284, WALTHAM MA 02451
Jeryl L Hilleman director C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Index Venture Associates Iii Ltd 10 percent owner 5TH FLOOR, 44 ESPLANADE, ST. HELIER, CHANNEL ISLANDS Y9 JE1 3FG
Index Venture Associates Iv Ltd 10 percent owner 44 ESPLANADE, ST. HELIER, CHANNEL ISLANDS Y9 JE4 9WG

Minerva Neurosciences (Minerva Neurosciences) Headlines

From GuruFocus